medigraphic.com
ISSN 1665-3254 (Impreso)
Revista Oficial de la Universidad Biomédica Rafael Guízar y Valencia A. C.

2005, Número 1-2

<< Anterior Siguiente >>

Plasticidad y Restauración Neurológica 2005; 4 (1-2)


Medicamentos estimulantes en el tratamiento del TDAH

Sauceda GJM, Maldonado DJM

Idioma: Español
Referencias bibliográficas: 34
Paginas: 75-80
Archivo PDF: 109.56 Kb.


RESUMEN

El trastorno por déficit de la atención con hiperactividad (TDAH) es en la actualidad una de las primeras causas de atención por los especialistas de salud mental en el mundo. Las principales manifestaciones clínicas las identifica la familia, la escuela o el consultorio del pediatra, neurólogo o psiquiatra. Dentro del tratamiento deberá contemplar un tratamiento biológico (medicamentos), psicológico (psicoterapia), educativo (pedagógico). Esta comunicación analiza el uso de fármacos, especialmente los psicoestimulantes sus características farmacológicas, indicaciones y efectos colaterales, de los 3 más importantes metilfenidato, dextroanfetamina y metilfenidato.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. AACAP OFFICIAL ACTION. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescent and adults. J Am Acad Child Adolesc Psychiatry. 2001;40(11):1352-1355.

  2. AACAP OFFICIAL ACTION. Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 supl):26s-49s.

  3. AACAP SPECIAL COMMUNICATION. National Institutes of Health Consensus Development Conference Statement: Diagnosis and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD). J Am Acad Child Adoles Psychiatry. 2000;39(2):182-193.

  4. Barkley RA. ADHD and the nature of self-control. Guilford, New York, 1997.

  5. Biederman J, Wilens TE, Mick E. Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder (ADHD): Effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652-1658.

  6. Biederman J, Wilens T, Mick E. Pharmacotherapy of attention deficit hyperactivity disorder reduces risk for substance use disorder in midadolescence. Pediatrics. 1999;104(2):e20.

  7. Carlson GA, Kelly KL. Stimulant rebound: how common is it and what does it mean? J Am Acad Child Adolesc Psychiatry 2003;13(2):137-142.

  8. Cox BM. Drug Tolerance and physical dependence. In: Principles of drug action: the basis of pharmacology. Pratt WB y Taylor P (eds), Churchill Livingstone, New York 1990:639-690.

  9. Dulcan MK, Martini DR, Lake MB (eds). Child and adolescent psychiatry. American Psychiatric Publishing, Arlington VA, 2003:259-323.

  10. Elia, Borcherding B, Rapoport J, Keysor C. Methylphenidate and amphetamine treatments of hyperactivity: are there true non-responders? Psychiatry Res 1991;36:141-155.

  11. Findling RL, Dogin JW. Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry 1998;59(7 supl):42s-49s.

  12. Goldman L, Genel M, Bezman R, Slantez P. Diagnosis and treatment of attention deficit-hyperactivity disorder. JAMA 1998;279;1100-1107.

  13. Greenhill LL. Stimulant-related growth inhibition in children: a review. En Gittelman M (ed): Strategic interventions for hyperactive children, ME Sharpe, New York 1981:39-63.

  14. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999:38(5):503-512.

  15. Hunt RD, Paguin A, Payton K. An update on assessment and treatment of complex attention-deficit hyperactivity disorder. Pediatr Ann 2001;30;(3):162-172.

  16. Klein RG, Manuzza S. The long-term outcome of attention deficit disorder/hyperkynetic syndrome. En: Sagvoilden T y Archer T (eds): Attention deficit disorder clinical and basic research. LEA, Hillsdale, NJ 1989:71-91.

  17. Kurlan R. Methylphenidate to treat ADHD is not contraindicated in children with tics. Mov Dis 2002;17:5-6.

  18. Marangell LB, Silver JM, Martinez JM, Yudofsky SC. Psychopharmacology. American Psychiatric Publishing, Washington 2002:151-170.

  19. Overmeyer S, Taylor E. Annotation: principles of treatment for hyperkynetic disorder: practice approaches for the U. K. J Child Psychol Psychiat 1999;40(8):1147-1157.

  20. Prince J. Clonidine for ADHA related sleep disturbances: A systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996;35:599-605.

  21. Riddle MA, Kastelic EA, Frosch E. Pediatric psychopharmacology., J Child Psychol Psychiat 2001;42 (1):73-90.

  22. Safer DJ, Allen RP. Absence of tolerance of the behavioral effect of methylphenidate in hyperactive and inattentive children. J Pediatr 1989;115:1003-1008.

  23. Salle FR, Stiller RI, Perel JM. Pemoline induced abnormal involuntary movements. J Clin Psychopharmacol 1989;9:125-129.

  24. Santosh PJ, Taylor E. Stimulant drugs. Eur Child Adolesc Psycchiatry 2000;9(suppl 1):127-143.

  25. Schachar R, Tannock R, Cunningham C. Behavioral, situational and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 1997;36:754-763.

  26. Shevell M, Schreiber R. Pemoline-associated hepatic failure: A critical analysis of the literature. Pediatr Neurol 1997;16:14-16.

  27. Smith BH, Pelham WE, Gnagy E, Yudell RS. Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence. J Am Acad Child Adolesc Psychiatry 1998;37 (3):314-321.

  28. Spencer TJ, Biederman J, Harding M. Growth deficits in ADHD children revisited: Evidence for disorder associated growth delays? J Am Acad Child Adolesc Psychiatry 1996;35:1460-1469.

  29. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 2000;9(1):77-97.

  30. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit hyperactivity disorder in children. J Clin Psychiatry 2002;63(supl 12):16-22.

  31. Swanson J, Gupta D. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 1999;66:295-305.

  32. Volkow ND, Wang GJ, Fowler J, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N. Annotation: the use of psychotropic medications in children: an American view. J Child Psychol Psychiat 2003;44(2):159-168.

  33. Weiss M, Weiss G. Attention deficit hyperactivity disorder. In: Lewis M (ed) Child and adolescent psychiatry, Lippincott Williams and Wilkins, Philadelphia 2002:645-670.

  34. Wolraich ML. Annotation: the use of psychotropic medications in children: an American view. J Child Psychol Psychiat 2003;44;2:159-168.




2020     |     www.medigraphic.com